Altimmune Inc. [NASDAQ: ALT] surged by $1.17 during the normal trading session on Tuesday and reaching a high of $24.99 during the day while it closed the day at $23.60. The company report on July 22, 2020 that Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID™, its Single Dose Intranasal Vaccine Candidate for COVID-19.
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company has entered into an agreement with Vigene Biosciences (“Vigene”) to manufacture AdCOVIDTM, Altimmune’s single-dose intranasal vaccine candidate for COVID-19. Vigene, a Rockville, Maryland-based award-winning Contract Development and Manufacturing Organization (CDMO), specializes in viral vectors and will deploy its capabilities to manufacture AdCOVID. Following recent positive pre-clinical data, Altimmune plans to start a Phase 1 clinical trial of AdCOVID in Q4 2020.
“Vigene is a fantastic partner to advance AdCOVID into Phase 1 clinical testing and beyond,” said Dr. Vipin K. Garg, President and CEO of Altimmune. Dr. Garg continued, “We believe Vigene’s deep experience in viral vector production and their collaborative, client focused approach will help facilitate Altimmune’s timeline for clinical development of AdCOVID.”.
Altimmune Inc. stock has also loss -24.84% of its value over the past 7 days. However, ALT stock has inclined by 663.75% in the 3 months of the year. Over the past six months meanwhile, it has gained 1189.62% and gained 1148.68% year-on date.
The market cap for ALT stock reached $795.56 million, with 15.11 million shares outstanding and 12.07 million shares in the current float. Compared to the average trading volume of 5.29M shares, ALT reached a trading volume of 1757643 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Altimmune Inc. [ALT]:
JMP Securities have made an estimate for Altimmune Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on July 28, 2020. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on February 24, 2020, representing the official price target for Altimmune Inc. stock. Previously, the target price had yet another raise to $8.30, while ROTH Capital analysts kept a Buy rating on ALT stock.
The Average True Range (ATR) for Altimmune Inc. is set at 3.72, with the Price to Sales ratio for ALT stock in the period of the last 12 months amounting to 155.99. The Price to Book ratio for the last quarter was 8.52, with the Price to Cash per share for the same quarter was set at 0.98.
ALT stock trade performance evaluation
Altimmune Inc. [ALT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.84. With this latest performance, ALT shares gained by 122.64% in over the last four-week period, additionally plugging by 1189.62% over the last 6 months – not to mention a rise of 904.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALT stock in for the last two-week period is set at 56.10, with the RSI for the last a single of trading hit 50.70, and the three-weeks RSI is set at 60.12 for Altimmune Inc. [ALT]. The present Moving Average for the last 50 days of trading for this stock 13.42, while it was recorded at 25.66 for the last single week of trading, and 5.11 for the last 200 days.
Altimmune Inc. [ALT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Altimmune Inc. [ALT] shares currently have an operating margin of -293.63. Altimmune Inc.’s Net Margin is presently recorded at -353.71.
Return on Total Capital for ALT is now -35.43, given the latest momentum, and Return on Invested Capital for the company is -42.83. Return on Equity for this stock declined to -43.74, with Return on Assets sitting at -37.72. When it comes to the capital structure of this company, Altimmune Inc. [ALT] has a Total Debt to Total Equity ratio set at 3.83. Additionally, ALT Total Debt to Total Capital is recorded at 3.69, with Total Debt to Total Assets ending up at 3.23. Long-Term Debt to Equity for the company is recorded at 3.26, with the Long-Term Debt to Total Capital now at 3.14.
Reflecting on the efficiency of the workforce at the company, Altimmune Inc. [ALT] managed to generate an average of -$820,805 per employee. Receivables Turnover for the company is 1.90 with a Total Asset Turnover recorded at a value of 0.11.Altimmune Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.60 and a Current Ratio set at 6.60.
Earnings per share (EPS) analysis for Altimmune Inc. [ALT] stock
With the latest financial reports released by the company, Altimmune Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALT.
Altimmune Inc. [ALT]: Insider Ownership positions
There are presently around $38 million, or 19.70% of ALT stock, in the hands of institutional investors. The top three institutional holders of ALT stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 617,007, which is approximately 255.929% of the company’s market cap and around 6.50% of the total institutional ownership; VANGUARD GROUP INC, holding 580,709 shares of the stock with an approximate value of $13.71 million in ALT stocks shares; and WINTON GROUP LTD, currently with $2.22 million in ALT stock with ownership of nearly -3.822% of the company’s market capitalization.
Positions in Altimmune Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 14 institutional holders increased their position in Altimmune Inc. [NASDAQ:ALT] by around 511,436 shares. Additionally, 15 investors decreased positions by around 218,619 shares, while 9 investors held positions by with 873,672 shares. The mentioned changes placed institutional holdings at 1,603,727 shares, according to the latest SEC report filing. ALT stock had 9 new institutional investments in for a total of 14,147 shares, while 9 institutional investors sold positions of 156,770 shares during the same period.